Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy
- PMID: 39064488
- PMCID: PMC11279000
- DOI: 10.3390/medicina60071059
Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy
Abstract
Background and Objectives: Postmenopausal vaginal discomfort is often attributed to vulvovaginal atrophy (VVA). Women with VVA experience symptoms such as vaginal dryness, itching, burning, irritation, and dyspareunia. Materials and Methods: This pilot study was conducted to assess the effects of a micro-ablative fractional CO2 laser on the clinical symptoms of VVA, as well as concordant sexual function. The severity of VVA symptoms was evaluated by a visual analogue scale (VAS), while the condition of the vaginal mucosa was evaluated using the Vaginal Health Index Score (VHSI). Sexual function was evaluated using the Female Sexual Function Index (FSFI) Questionnaire. Results: Our cohort included 84 sexually active postmenopausal women with bothersome VVA, leading to sexual health complaints. The mean age of the participants in our study was 55.2 ± 5.4 years, with an average postmenopausal period of 6 ± 4.8 years. The age of our patients and the length of their postmenopausal period exhibited a significant negative correlation with VHSI scores, while a longer postmenopausal period was associated with increased severity of vaginal dryness and dyspareunia. Baseline VHSI values showed that 65% of patients had atrophic vaginitis with pronounced VVA symptoms (70.2% experienced vaginal itching, 73.8% reported vaginal burning, 95.3% had vaginal dryness, and 86.1% suffered from dyspareunia). Lower VHSI values significantly correlated with lower FSFI scores, while more severe VVA symptoms scores correlated with lower FSFI scores. VVA symptoms were significantly less severe after treatment. VHIS regained high non-atrophic values in 98.8% of patients post-treatment (p < 0.001). FSFI total and domain scores were significantly higher after treatment (p < 0.001). Conclusions: Our study revealed that fractional CO2 laser is a useful treatment option to alleviate VVA symptoms and improve vaginal health and sexual functioning in postmenopausal women.
Keywords: female sexual health; fractional CO2 laser; menopause; vulvovaginal atrophy.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.Climacteric. 2015 Apr;18(2):219-25. doi: 10.3109/13697137.2014.975197. Epub 2014 Dec 16. Climacteric. 2015. PMID: 25333211
-
A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.Climacteric. 2014 Aug;17(4):363-9. doi: 10.3109/13697137.2014.899347. Epub 2014 Jun 5. Climacteric. 2014. PMID: 24605832
-
Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.J Sex Med. 2022 May;19(5):761-770. doi: 10.1016/j.jsxm.2022.02.027. Epub 2022 Mar 31. J Sex Med. 2022. PMID: 35370104
-
Efficacy of CO2 laser treatment in postmenopausal women with vulvovaginal atrophy: A meta-analysis.Int J Gynaecol Obstet. 2022 Aug;158(2):241-251. doi: 10.1002/ijgo.13973. Epub 2021 Oct 30. Int J Gynaecol Obstet. 2022. PMID: 34625949 Review.
-
Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.Gynecol Endocrinol. 2021 Aug;37(8):740-745. doi: 10.1080/09513590.2021.1931100. Epub 2021 May 26. Gynecol Endocrinol. 2021. PMID: 34036849
Cited by
-
Comment on Jankovic et al. Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy. Medicina 2024, 60, 1059.Medicina (Kaunas). 2025 Apr 30;61(5):831. doi: 10.3390/medicina61050831. Medicina (Kaunas). 2025. PMID: 40428789 Free PMC article.
-
Reply to Broomfield et al. Comment on "Jankovic et al. Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy. Medicina 2024, 60, 1059".Medicina (Kaunas). 2025 Apr 30;61(5):832. doi: 10.3390/medicina61050832. Medicina (Kaunas). 2025. PMID: 40428790 Free PMC article.
References
-
- Portman D.J., Gass M.L.S. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary Syndrome of Menopause: New Terminology for Vulvovaginal Atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–1068. doi: 10.1097/GME.0000000000000329. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources